Highlights
- Aurobindo Pharma USA completed the acquisition of Lannett Company.
- Lannett became a wholly owned subsidiary on June 29, 2026.
- The acquisition was completed after receiving U.S. FTC approval.
Aurobindo Pharma Ltd. (NSE:AUROPHARMA) informed the National Stock Exchange (NSE) and BSE that its wholly owned subsidiary, Aurobindo Pharma USA Inc. (APUSA), has completed the acquisition of Lannett Company, Inc., USA from Lannett Seller Holdco, Inc. The completion follows approval from the U.S. Federal Trade Commission (FTC), which was received on June 18, 2026. The company made the disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Source: Analysis by Kalkine
Lannett Becomes Wholly Owned Subsidiary
According to the company, the acquisition became effective on June 29, 2026. From that date, Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc. and will operate under the name Lannett Company LLC.
The company had earlier informed stock exchanges about the proposed acquisition through its letter dated June 19, 2026, followed by a press release issued on June 22, 2026.
Integration Process Begins
Aurobindo Pharma stated that the integration process will begin immediately following the completion of the acquisition. According to the company, the transition will focus on ensuring uninterrupted access to critical medicines, maintaining relationships with partners and supporting employees during the integration process.
The company added that combining the capabilities and resources of both businesses is intended to improve the availability of essential medicines while supporting patients, customers and other stakeholders.
More Than 400 Employees Join APUSA
As part of the acquisition, Aurobindo Pharma USA has welcomed more than 400 employees from Lannett into its organisation. According to the company, the addition of these employees is expected to strengthen its talent base and operational capabilities.
The company also acknowledged the contribution of Lannett's management team in facilitating the completion of the transaction and supporting the transition process.
Acquisition Follows Regulatory Clearance
The completion of the acquisition follows the receipt of approval from the U.S. Federal Trade Commission on June 18, 2026. With the regulatory approval secured, the transaction has now been completed and Lannett has officially become part of the Aurobindo Pharma group through APUSA.
Key Risks
- Integration challenges could affect operational efficiency.
- Employee retention may influence post-acquisition transition.
- Regulatory compliance remains important across combined operations.
- Integration costs may affect near-term financial performance.
Summary
Aurobindo Pharma announced that its wholly owned subsidiary, Aurobindo Pharma USA Inc., has completed the acquisition of Lannett Company following U.S. Federal Trade Commission approval. Effective June 29, 2026, Lannett became a wholly owned subsidiary operating as Lannett Company LLC. The company has started the integration process and welcomed more than 400 Lannett employees.
FAQs
Q: When did Aurobindo Pharma complete the Lannett acquisition?
A: The acquisition became effective on June 29, 2026, after receiving U.S. Federal Trade Commission approval.
Q: What is Lannett's status after the acquisition?
A: Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc. and now operates as Lannett Company LLC.
Q: How many employees joined Aurobindo Pharma through the acquisition?
A: According to the company, more than 400 Lannett employees have joined Aurobindo Pharma USA following the acquisition.